Relevance of NUTURE Study Findings for Patients, Payers, Providers
Important takeaways for patients, payers, and providers are covered by expert faculty.
This is a video synopsis/summary of a Between the Lines featuring Thomas Crawford, M.D.; and Jim Kenney, R.Ph., MBA.
Crawford and Kenney discuss the implications of spinal muscular atrophy therapy studies for patients, providers, and payers. While transformational for a previously fatal pediatric disease, the extremely high costs of these innovative therapies (e.g.,nusinersen costs $125,000 per dose) raises societal questions about equitable access and sustainability.
As more gene and cell therapies emerge for other rare diseases with the potential for significant benefits, balancing innovation incentives and cost management across the healthcare ecosystem will be an ongoing challenge. Payers must rapidly get up to speed on unfamiliar diseases and make coverage decisions with limited long-term data.
Key next steps include continued education and collaboration among all stakeholders — patients, providers, payersand policymakers — will be needed to ensure patient access while supporting further progress.
Video synopsis is AI-generated and reviewed by Managed Healthcare Executive® editorial staff.
Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease
December 12th 2024Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene therapies for sickle cell disease, which offer great potential but have had slow uptake.
Read More
Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024
October 18th 2024Statins have had an evolving role in the management of cardiovascular risk in people living with HIV, explained Michelle Cespedes, M.D., M.S., professor of medicine, Icahn School of Medicine at Mount Sinai and Mount Sinai Health System.
Read More
